<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846157</url>
  </required_header>
  <id_info>
    <org_study_id>NKMGI 4-06</org_study_id>
    <nct_id>NCT00846157</nct_id>
  </id_info>
  <brief_title>Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients</brief_title>
  <acronym>NKCell</acronym>
  <official_title>R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NKBio Co.Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NKBio Co.Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell
           to R-CHOP therapy with DLBCL patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP plus Natural Killer Cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKM injection</intervention_name>
    <description>NKCell about 100mg IV for 6times in each chemotherapy period.</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>NKCell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women of the age between 20 and 70

          2. The patients who have measurable lesion using radiograph and have not received
             chemotherapy and radiation therapy after confirming DCBCL.

          3. The patients with Ann arbor Ⅰ, Ⅱ, Ⅲ, Ⅳ

          4. The patients who have not received NK / T-Cell lymphocyte therapy.

          5. The patients who are expected to survive for at least 3 months.

          6. The patients who or whose representative voluntary have written informed consent
             before performance of any study-related procedure.

          7. Women of child bearing potential must have a negative pregnancy test within 7 days
             prior to study registration and agree to use adequate birth control during study
             treatment.

          8. The patients with ADL classification (ECOG) scale 0, 1, 2

          9. Patients who satisfy following hematologic criteria

               -  WBC ≥ 3,000 / ㎕

               -  platelet count ≥ 75,000 / ㎕

               -  serum total bilirubin ≤ two times of upper limit of normal values of each
                  laboratory

               -  serum creatinine ≤ two times of upper limit of normal values of each laboratory

         10. lymphoma patients who satisfy the following criteria

               -  good renal function (GFR&gt; 50)

               -  good hepatic function (total bilirubin level ≤ three times of upper limit of
                  normal values of each test laboratory transaminases ≤ 5 times of the upper limit
                  of normal value of each testing laboratory)

         11. The patients with negative HIV surface antigen

         12. The patients with negative HBV

         13. The patients with negative HCV

         14. The patients who have not received immunotherapy.

         15. The patients who have not experienced tuberculosis infection within recent 6 months.

        Exclusion Criteria:

          1. The minors under 20 years of age (In accordance with Civil Code)

          2. The patients diagnosed with other types of lymphoma

          3. The patients who have central nervous system or meningeal involvement by lymphoma.

          4. The patients who have contraindication of chemotherapy regimen

          5. The patients with another active severe disease.

          6. The patients who have history of cancer within 5 years

          7. Uncontrolled hypertension patients

          8. The patients who have hypersensitivity to Erythropoietin.

          9. The patients who have the following diseases or the experience to have following
             disease within 3 months.

               -  Myocardial infarction

               -  Unstable coronary disease

               -  Uncontrolled cardiac insufficiency.

               -  Venous thrombosis

               -  Pulmonary embolism

         10. The patients who have experience to be treated with the pharmaceutical for clinical
             trials.

         11. Pregnant and lactating women or women of childbearing age not using adequate
             contraceptive method.

         12. The patients with clinically serious bacterial, viral or fungal infection

         13. The patients of the test group who have the problem in NK cell cultures (Investigator
             will decide on this criteria with basis generated during NK cell culture)

         14. Patients with autoimmune diseases

         15. The patients who underwent visceral resection related with Lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok-Goo Cho, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic Hematopoietic Stem Cell Transplantation Center in The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of korea</name>
      <address>
        <city>Banpo-Dong 505</city>
        <state>Seoul</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>June 26, 2011</last_update_submitted>
  <last_update_submitted_qc>June 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lee,Jae-Kyu</name_title>
    <organization>Bio Bisiness Headquater/Assistant Manager in Cell Manufacture Team</organization>
  </responsible_party>
  <keyword>natural killer cell</keyword>
  <keyword>DLBCL (Diffuse Large B Cell Lymphoma)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

